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vs. NT in 79%, 56%, and 36% of model runs, respectively.
CONCLUSIONS: For the management of BCBM patients, ZA
is the preferred bisphosphonate as it is more effective and less
expensive than other IV agents or even no therapy.
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OBJECTIVES: The primary core analysis of the BIG 1–98 study
showed that in postmenopausal women with hormone receptor
positive (HR+) early breast cancer, the aromatase inhibitor (AI)
letrozole (LET) signiﬁcantly reduced the risk of recurrence by
19% overall (95% CI 7–30%) and the risk of relapse in distant
sites by 27% overall (CI 12–40%) compared with tamoxifen
(TAM). Letrozole demonstrated non-signiﬁcant improvements in
overall survival and contralateral breast cancer. LET patients had
reduced risks of endometrial cancer and venous thromboem-
bolism (VTE), but increased risks of mild/moderate hypercho-
lesteraemia, cardiac events and fractures. This study reports the
cost-effectiveness of initial adjuvant therapy with LET vs. TAM
in postmenopausal women with HR+ early stage breast cancer
from the UK NHS perspective based on preliminary analyses of
published results of the BIG 1–98 trial. METHODS: A Markov
model describes the occurrence of contralateral tumours; locore-
gional recurrence; soft tissue, bone, and visceral metastases, and
treatment side effects (endometrial cancer, VTE, hip fractures,
other fractures, hypercholesterolaemia, and MI). Clinical para-
meters for TAM were based on published results of the BIG 1–98
trial and other published studies, as were health-state utilities.
Corresponding probabilities for LET were calculated by apply-
ing RRs for LET vs. TAM from the BIG 1–98 study. Costs of
breast-cancer care were estimated using UK patient-level
resource use data. Lifetime costs (2004UK£) and QALYs were
estimated for HR+ women aged 61 years at diagnosis, dis-
counted at 3.5% annually. RESULTS: Compared with TAM,
LET results in an additional 0.33 QALYs (12.84 vs. 12.51).
These beneﬁts are obtained at an additional cost of £4079
(£12,474 vs. £8395). Cost-effectiveness of LET vs. TAM is
£12,321 (95% CI £2672-£23,889) per QALY saved. CON-
CLUSION: Adjuvant treatment with letrozole is cost-effective
from a UK NHS perspective compared with tamoxifen and
should be considered in women diagnosed with HR+ early breast
cancer.
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OBJECTIVE: TS-1 is a newly developed oral anticancer drug.
We previously reported the treatment costs for gastric cancer in
Japan and suggested that TS-1 is cost saving compared to con-
ventional intravenous chemotherapy. The aim of this study is to
examine health utilities in gastric cancer patients and to assess
the cost-utility of TS-1. METHODS: Patients with advanced or
recurrent gastric cancer who were able to ingest meals were 
identiﬁed retrospectively from the ordering system database of
Showa University Hospital between January 1998 and July
2001. The utilities of the patients during chemotherapy were
assessed by oncology pharmacists on the basis of medical records
(including information on mobility, meal ingestion, pain, and
other symptoms), using the rating scale method, time trade-off
method, standard gamble method and EQ-5D mapping proce-
dure. The costs of the patients were calculated on the basis of
hospital billing data. Cost-utility analysis was conducted from a
societal perspective. RESULTS: Of the 23 patients who met the
inclusion criteria, 13 received TS-1 and 10 received conventional
intravenous chemotherapy. Mean (SD) utilities as measured by
the rating scale method, time trade-off method, standard gamble
method and EQ-5D mapping procedure were 0.89 (0.12), 0.90
(0.11), 0.94 (0.07), and 0.84 (0.18), respectively, in the TS-1
group. The corresponding utilities in the conventional intra-
venous chemotherapy group were 0.65 (0.18), 0.66 (0.18), 0.81
(0.12), and 0.52 (0.23), respectively. The utilities of the TS-1
were signiﬁcantly (P < 0.05) higher than those of conventional
intravenous chemotherapy by every technique. The mean
monthly cost during chemotherapy was signiﬁcantly lower in the
TS-1 group than in the conventionalintravenous chemotherapy
group (€2481 vs. €6458, P < 0.05). CONCLUSION: TS-1, an
oral anticancer agent, is a dominant strategy with a lower cost
and a greater health outcome than conventional intravenous
chemotherapy in patients with advanced or recurrent gastric
cancer.
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OBJECTIVES: In the Arimidex, Tamoxifen Alone or in Combi-
nation (ATAC) trial, anastrozole produced signiﬁcantly longer
disease-free survival and time to recurrence compared with
tamoxifen in hormone receptor-positive (HR+) postmenopausal
women with early breast cancer after 5 years of treatment.
(ATAC Trialists’ Group. Lancet 2005;365:60–2) Based on these
ATAC results, the cost-utility of anastrozole versus tamoxifen is
estimated from the perspective of the UK National Health
Service (NHS). METHODS: A Markov model and Weibull sur-
vival curves ﬁtted to trial data were used to project 5-year out-
comes from the ATAC trial to an actuarial time point of 25 years.
Resource utilisation data were obtained primarily from a physi-
cian survey. Unit costs (2003–4 UK£) were obtained from routine
NHS sources. Utility scores for relevant health states were
obtained from 26 representative UK patients, using a standard
gamble technique. Costs and beneﬁts were discounted at the
annual rate of 3.5%. All effectiveness and cost parameters
subject to uncertainty were varied in a probabilistic analysis.
Incremental cost effectiveness ratios (ICERs), 95% CIs, and
acceptability curves were calculated. RESULTS: The estimated
25 year ICER of anastrozole compared with generic tamoxifen
was £7811 (£219–31,438) per QALY gained with a probability
of the order of 90% that it lies below £20,000 per QALY gained.
The results were sensitive to the time horizon of the model and
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the assumptions about the length of the treatment beneﬁt.
CONCLUSIONS: Anastrozole is a cost-effective alternative to
tamoxifen for the adjuvant treatment of postmenopausal women
with HR+ early breast cancer from the UK NHS perspective,
with the cost per QALY gained with anastrozole falling well
within the range considered acceptable for reimbursement in the
UK.
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OBJECTIVE: To estimate the cost and effects (measured in
QALYs) of fulvestrant as replacement of exemestane in the
second line treatment of postmenopausal women with advanced
breast cancer (ABC) in Greece. The preliminary results are pre-
sented in this analysis. METHODS: A Markov model was used
in order to compare cost effectiveness of two patient cohorts
receiving: fulvestrant (cohort A) or exemestane (cohort B) as 2nd
line treatment, megestrol acetate (A, B) as 3rd line treatment and
a palliative care package (A, B). The perspective of the study was
that of the National Health care System. Clinical evidence was
derived from published clinical trials. Treatment effects were esti-
mated in QALYs. Direct costs included drug therapy, oncologist
visits, monitoring tests and adverse events treatment. Informa-
tion on resource use was obtained from a panel of 3 oncology
key opinion leaders. As patients can use either public or private
sector, charges of both sectors for year 2005 will be used. Public
sector prices are used in this analysis. The time horizon of the
study was 11 years and the discount rate used for both costs and
QALYs was 3.5%. RESULTS: Cohort A had a higher propor-
tion of responders with a longer duration on 2nd line treatment.
In a cohort of 100 patients, fulvestrant produces 8.1 extra
QALYs at a 18% extra cost compared to exemestane resulting
in an incremental cost effectiveness ratio (ICER) of €35,633 per
QALY. However, as public sector charges highly underestimate
cost of treatment, further scenario analysis will be carried out in
order to capture true cost of treatment in Greece. CONCLU-
SIONS: Fulvestrant proves to be more beneﬁcial than exemes-
tane at an extra cost of €35,633 per QALY. Fulvestrant produces
extra beneﬁt with a reasonable extra cost for ABC patients in
Greece.
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OBJECTIVES: Four chemotherapy regimens: gemcitabine-
paclitaxel (Gem/Pac), paclitaxel in monotherapy (Pac), docetaxel
in monotherapy (Doc) and docetaxel-capecitabine in association
(Doc/Cap), are commonly used in the ﬁrst-line treatment of
metastatic breast cancer after anthracyclines failure. The purpose
of the study is to rank these strategies according to their incre-
mental cost-utility ratios. METHODS: A Markov model was
constructed in order to evaluate all 4 protocols, based on efﬁ-
cacy and tolerance data from recently published phase III studies.
Ravdin showed superiority for Doc compared to Pac in
monotherapy. O’Shaughnessy for the Doc/Cap regimen and the
phase III registration study for the Gem/Pac showed superiority
for Doc/Cap and Gem/Pac compared to Doc and Pac respec-
tively. An indirect comparison of these 4 regimens was con-
ducted, all possible scenarii with averages and extreme data were
tested. The costs were calculated by adding DRG costs, onerous
drug costs reimbursed over DRGs and transportation expenses.
Costs of severe toxicities, diagnosis and palliative care, were
taken into account. RESULTS: The Gem/Pac strategy appears to
be the most effective compared to Doc, Pac and Doc/Cap. In
terms of survival, Gem/Pac has an additional efﬁcacy of 16.5
weeks and an incremental cost-effectiveness (ICER) of €5570
compared to Doc/Cap, with a ICER of €18,000 per year of life
gained. In terms of survival adjusted to quality of life, the efﬁ-
cacy gain is 12.1 weeks and the ICER is €22,000 per year of life
gained. When the D8 gemcitabine is administered at home, the
Gem/Pac ICER is €12,000 year of life gained. CONCLUSION:
The incremental cost-effectiveness ratios of Gem/Pac regimen are
between €10,000 and €22,000 per year of life gained, still below
the limits recognized as reasonable at the international level.
Another advantage of the Gem/Pac combination therapy is to
allow home care on day 8 of the cycle.
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OBJECTIVES: Since January 1, 2004 several changes concern-
ing payment mechanisms became effective. These changes
include changes in drug costs (new deﬁnition for pharmacy add-
ups (affecting primarily very low and high priced drugs, and
mandatory manufacturer discounts), the introduction of a DRG-
system for hospital care and a new tariff system for private prac-
tices. The impact of these changes on health economic
evaluations using the third party payer perspective was evalu-
ated. METHODS: Resource utilization data for two different
intravenous therapies for an oncologic indication was collected
from 89 quarterly fee listings of ofﬁce based specialists in 2000.
Findings were projected to the hospital care setting and an oral
treatment option. The resource utilization data for each therapy
and treatment setting were analyzed 3 times: 1) drug costs, physi-
cian services and hospital per diem rates (2002); 2) drug costs,
physician services and hospital per diem rates (2004); and 3)
drug costs, physician services and hospital DRG rates (2005).
RESULTS: Compared to the 2002 analyses treatment cost in
2005 in private practices decreased by 3–18%, mainly due to
lower drug costs. Cost for hospital treatment changed in differ-
ent directions depending on the type of hospital. Treatment cost
in municipal hospitals increased by 52%–229%, whereas cost in
university hospitals decreased by 1%–65%. CONCLUSION:
Recent changes due to health care reforms and resulting changes
in payment mechanisms had a major impact on calculating treat-
ment costs from a third party payer perspective in Germany.
Although these results refer to an oncologic indication, it is very
likely that similar differences will be observed in other thera-
peutic areas as well. Results of health economic evaluations from
the third party payer perspective performed prior to 2005, 
particularly those involving hospital care and not using DRGs
may be misleading today and re-analysis should be seriously 
considered.
